 "The company already enjoys a 67-68 per cent share of the respiratory drugs market in India and has potential for a 14-15 per cent growth")
Shilpa Medicare on Tuesday said it has received approval from the US health regulator for Irinotecan HCL injection, used for treatment of certain kind of cancers.
The company has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL injection USP in the strengths 40 mg/2mL and 100 mg/5mL (20mg/mL) single dose vials, Shilpa Medicare said in a BSE filing.
Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum, the company added.
Quoting IQVIA MAT second quarter 2018 data, Shilpa Medicare said the US market for Irinotecan HCL is approximately $18 million.
Shares of Shilpa Medicare were trading 3.80 per cent up at Rs 398.65 apiece on BSE.
